Donor Selection in T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 2, 2013, Pages 180-184

  Ciurea, Stefan O ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti HLA antibodies; Donor selection; Haploidentical stem cell transplantation

Indexed keywords

HLA ANTIBODY; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

AGE; ALLELE; ALLOIMMUNITY; CELL COUNT; DONOR SELECTION; GENDER; GRAFT FAILURE; GRAFT RECIPIENT; HAPLOTYPE; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NATURAL KILLER CELL; REVIEW;

DONOR SELECTION; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; T-LYMPHOCYTES;

EID: 84872620885     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.08.007     Document Type: Review

References (40)

1. Luznik L., Jalla S., Engstrom L.W., et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001, 98:3456-3464.
2. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced-intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
3. Ciurea S.O., Mulanovich V., Saliba R.M., et al. Improved early outcomes using a T-cell-replete graft compared with T cell-depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, in press.
4. Ciurea S.O., de Lima M., Cano O., et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009, 88:1019-1024.
5. Ciurea S.O., Thall P.F., Wang X., et al. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011, 118:5957-5964.
6. Takanashi M, Atsuta A, Fujiwara K, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantation. Blood. 200;116:2839-2846.
7. Cutler C., Kim H.T., Sun L., et al. Donor-specific anti-HLA antibodies predict outcomes in double umbilical cord blood transplantation. Blood 2011, 118:6691-6697.
8. Xu H, Chilton PM, Tanner MK, et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood. 108:3611-3619.
9. Yoshihara S., Maruya E., Taniguchi K., et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012, 47:508-515.
10. Rocha V., Labopin M., Gluckman E., et al. Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first CR: results of a European survey. J Clin Oncol 2002, 20:4324-4330.
11. Dominietto A., Lamparelli A.M., Van Lint M.T., et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic bone marrow transplantation. Blood 2002, 100:3930-3934.
12. Gorin N.C., Labopin M., Rocha V., et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcomes. Blood 2003, 102:3043-3051.
13. Bachar-Lustig E., Rachamim N., Li H.W., et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995, 1:1268-1273.
14. + progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Ann NY Acad Sci 1999, 872:336-348.
15. Gajewski J., Johnson V.V., Sandler S.G., et al. A review of transfusion practice before, during and after hematopoietic progenitor cell transplantation. Blood 2008, 112:3036-3047.
16. Guttridge M.G., Sidders C., Booth-Davey E., et al. Factors affecting volume reduction and red blood cell depletion of bone marrow on the COBE Spectra cell separator before hematopoietic stem cell transplantation. Bone Marrow Transplant 2006, 38:175-181.
17. Morishima Y., Sasazuki T., Inoko H., et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA matched HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002, 99:4200-4206.
18. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004, 104:1923-1930.
19. Lee S.J., Klein J., Haagerson M., et al. High-resolution HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
20. Kasamon Y.L., Luznik L., Leffell M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplant cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010, 16:533-542.
21. Ciurea S.O., Saliba R.M., Rondon G., et al. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatch related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant 2011, 17:923-929.
22. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
23. Ruggeri L., Mancusi A., Burchielli E., et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Science 2008, 40:84-90.
24. Gagne K., Brizard G., Gueglio B., et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002, 63:271-280.
25. Huang X.J., Zhao X.Y., Liu D.H., et al. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem-cell transplantation without in vitro T-cell depletion. Leukemia 2007, 21:848-851.
26. Symons H.J., Leffell M.S., Rossiter N.D., et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatched and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010, 16:533-542.
27. Cooley S., Weisdorf D.J., Guethlein L.A., et al. Donor selection for natural killer receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
28. Bross D.S., Tutschka P.J., Farmer E.R., et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984, 63:1265-1270.
29. Randolph S.S.B., Gooley T.A., Warren E.H., et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004, 103:347-352.
30. Weisdorf D., Hakke R., Blazar B., et al. Risk factors for acute graft-versus-host disease in histocompatible donor marrow transplantation. Transplantation 1991, 51:1197-1203.
31. Carlens S., Rihgden O., Remberger M., et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single-center analysis. Bone Marrow Transplant 1998, 22:755-761.
32. Loren A.W., Bunin G.R., Boudreau C., et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:758-769.
33. Huo M.R., Xu L.P., Li D., et al. The effect of HLA disparity on clinical outcomes after HLA-haploidentical blood and marrow transplantation. Clin Transplant 2012, 26:284-291.
34. Harris D.T., Schumacher M.J., LoCascio J., et al. Immunoreactivity of umbilical cord blood and postpartum maternal peripheral blood with regard to HLA-haploidentical transplantation. Bone Marrow Transplant 1994, 14:63-68.
35. Claas F.H., Gijbels Y., van der Velden-de Munck J., et al. Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life. Science 1988, 24:1815-1817.
36. Burlingham W.J., Grailer A.P., Heisey D.M., et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. N Engl J Med 1998, 339:1657-1664.
37. Polchi P., Lucarelli G., Galimberti M., et al. Haploidentical bone marrow transplantation from mother to child with advanced leukemia. Bone Marrow Transplant 1995, 16:529-535.
38. Tamacki S., Ichinohe T., Matsuo K., et al. Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts. Bone Marrow Transplant 2001, 28:375-380.
39. Van Rood J.J., Loberiza F.R., Zhang M.J., et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haplodentical sibling. Blood 2002, 99:1572-1577.
40. Stern M., Ruggeri L., Mancusi A., et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008, 112:2990-2995.